A recent study published in the Frontiers in Endocrinology journal showed that heart failure with preserved ejection fraction ...

Rheumatoid arthritis (RA) is associated with a higher rate of heart failure subtypes, according to a study published online ...

Rheumatoid arthritis (RA) is associated with a higher rate of heart failure subtypes, according to a study published o ...

Rates of heart failure with preserved ejection fraction (HFpEF) were doubled in patients with rheumatoid arthritis (RA) ...

Patients who have heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and high body mass index ...

UK: In a secondary analysis of the FINEARTS-HF randomized clinical trial, researchers found that finerenone, a novel ...

SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.

In infants with cardiomyopathy-associated chronic HF, baseline LVEF of less than 40% and β blocker use indicate a decreased chance of LVEF normalization.

From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for patients with heart failure and a left ventricular ejection fraction (LVEF) ...

and higher in epidemiological studies than in clinical trials. Mortality rates compared with heart failure with reduced ejection fraction (HFREF) appear to be strongly influenced by the type of ...

Patients with ejection fraction <40% were excluded ... placebo subjects were taking open-label ACE inhibitors—was also higher than predicted. [19] As for the other nonprimary outcome measures ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...